Beacon Capital Management LLC (Tennessee)’s Takeda Pharmaceutical TAK Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-23	Closed	-$356	–	1139
2023 Q4	$356	Hold	23	–	–	﹤0.01%	937
2023 Q3	$361	Hold	23	–	–	﹤0.01%	976
2023 Q2	$361	Hold	23	–	–	﹤0.01%	976
2023 Q1	$379	Hold	23	–	–	﹤0.01%	896
2022 Q4	$359	Hold	23	–	–	﹤0.01%	946
2022 Q3	$0	Hold	23	–	–	﹤0.01%	962
2022 Q2	$0	Hold	23	–	–	﹤0.01%	954
2022 Q1	$0	Buy	+23	New	+$338	﹤0.01%	954

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s TAK Position: Q1 2024 in Review

Beacon Capital Management LLC (Tennessee) sold out of Takeda Pharmaceutical (TAK) in Q1 2024, closing a stake of 23 shares — an estimated $356 sold.

Beacon Capital Management LLC (Tennessee) first reported a position in TAK in Q1 2022 and held it in 8 quarters. The position peaked at $379 in Q1 2023. 313 funds tracked by Wall St. Rank hold TAK as of Q1 2024.

Beacon Capital Management LLC (Tennessee) reported no remaining Takeda Pharmaceutical position as of Q1 2024 after selling out during the quarter.
Beacon Capital Management LLC (Tennessee) sold 23 Takeda Pharmaceutical shares in Q1 2024, an estimated $356.
Beacon Capital Management LLC (Tennessee) first reported a position in Takeda Pharmaceutical in Q1 2022 and held it in 8 quarters.
Beacon Capital Management LLC (Tennessee)'s Takeda Pharmaceutical position peaked at $379 in Q1 2023.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2024.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q1 2024, filed 16 May 2024.